A5078788587- Hemophilia Treatment and Research
- Blood Coagulation and Thrombosis Mechanisms
- Platelet Disorders and Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood properties and coagulation
- Hemostasis and retained surgical items
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Systemic Lupus Erythematosus Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Chronic Myeloid Leukemia Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Hemoglobinopathies and Related Disorders
- Pregnancy-related medical research
- Atrial Fibrillation Management and Outcomes
- Cardiovascular Issues in Pregnancy
- Infective Endocarditis Diagnosis and Management
- Neurogenetic and Muscular Disorders Research
- Bacterial Identification and Susceptibility Testing
- Chronic Lymphocytic Leukemia Research
- Cancer-related gene regulation
- Antimicrobial Resistance in Staphylococcus
Hôpital Louis Pradel
2019-2025
Hospices Civils de Lyon
2016-2025
Lille’s Cardiology Hospital
2022-2025
Hôpital Femme Mère Enfant
2022
Université Claude Bernard Lyon 1
2019-2022
Abstract Introduction Early prophylaxis is the gold standard of care for severe haemophilia. The development subcutaneous Factor VIII (FVIII) mimetics, such as emicizumab, has significantly reduced disease burden and improved protection against bleeding episodes. Despite its benefits, emicizumab does not fully normalize haemostasis, requiring additional FVIII treatment surgical procedures management breakthrough bleeding. In these cases, extended or ultra‐extended half‐life products are most...
Abstract Introduction Hemophilia is a rare constitutional bleeding disorder due to deficiency in Factor VIII or IX. Recurrent hemarthroses, one of the major complications disease, lead hemophilic arthropathy, disabling condition that requires early diagnosis. Traditionally, clinical examination and plain film radiography have been used diagnose arthropathy. Magnetic resonance imaging (MRI) ultrasound can be more useful for diagnosing soft‐tissue changes. However, but each these methods has...
In patients with FXI deficiency, the risk of surgery-related bleeding is poorly correlated plasma activity (FXI:C); latter can therefore not be used as a reliable predictor in surgeries.The aim this retrospective study was to determine whether thrombin generation assay (TGA) could evaluate FXI-deficient patients. TGA parameters were compared FXI:C values, haemostatic treatments and surgical outcomes.All followed at haemophilia treatment care centre (Lyon, France) < 50IU/dL, for whom baseline...
Abstract Acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder. We report herein case of AVWS due to monoclonal gammopathy undetermined significance, in which transient but prolonged response treatment by intravenous immunoglobulin (IVIG) was observed. The diagnosis fortuitously made preoperative setting for neurosurgery, after biological exploration an isolated activated partial thromboplastin time. confirmed accelerated clearance infused plasma-derived factor (VWF)...
Abstract Introduction Lightening the injection burden is commonly believed to improve prophylaxis adherence. Efmoroctocog alfa (rFVIIIFc) first recombinant FVIII‐Fc fusion protein available in France. This clotting factor with an extended half‐life could thus medication Aim The study primarily aimed assess real‐life impact on adherence of haemophilia A patients, when switching from a standard FVIII. Methods was observational, monocentre, non‐interventional aiming at assessing patients'...
Abstract Introduction and aim Severe haemophilia B (HB) is characterized by spontaneous bleeding episodes, mostly into joints. Recurrent bleeds lead to progressive joint destruction called haemophilic arthropathy. The current concept of prophylaxis aims at maintaining the FIX level >3–5 IU/dL, which effective reducing incidence Extended half‐life molecules make it easier achieve these target trough levels compared standard concentrates. We previously reported that fusion a recombinant...
The risk of pregnancy-related venous thromboembolism is high in patients with inherited thrombophilia. aim this study was to compare the pregnancy related-venous women protein C (PC) deficiency heterozygous factor V Leiden mutation. 145 consecutive pregnant confirmed PC or mutation were prospectively enrolled study. Lyon thromboembolism-risk score used individually tailor antithrombotic prophylaxis. use a validated clinical presents advantage have homogenous management having similar...
Abstract Background Efmoroctocog alfa (rFVIIIFc) is an extended half‐life FVIII used notably in surgery for patients with haemophilia A. More information needed of its usage real‐life. Methods Adult HA followed at the Lyon Comprehensive Hemophilia Care Center who underwent a rFVIIIFc were included this retrospective analysis. The pharmacokinetics was assessed by plasma factor VIII clotting activity (FVIII:C) using both one‐stage (OSA) and chromogenic substrate (CSA) assays. Results A total...
Hemophilia B (HB) is rare X-linked bleeding disorder characterized by coagulation factor IX (FIX) deficiency. Severe HB spontaneous and prolonged episodes, mostly into joints. Recurrent bleeds lead to progressive joint destruction called hemophilic arthropathy, may require replacement. The current concept of prophylaxis aims at maintaining the FIX level > 3-5 IU/dL, which effective reducing incidence life-threatening arthropathy. Extended half-life molecules make it easier achieve these...
Women with rare bleeding disorders (RBDs) can be exposed throughout their life to several complications such as menorrhagia or hemorrhagic during pregnancies and deliveries. Among RBDs, factor XIII deficiency leads life-threatening hemorrhages intracranial hemorrhage, women reproductive period may experience gynecological obstetric complications, more specifically recurrent miscarriages due the role of FXIII in placenta attachment. Because rarity disease, recommendations for treatment are...